{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:14:07Z","timestamp":1745381647675,"version":"3.40.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Introduction and importance:<\/jats:title>\n            <jats:p>Chronic myeloid leukemia (CML) is characterized by a BCR-ABL1 fusion gene of the Philadelphia chromosome, which is mutually exclusive of genetic abnormalities associated with the myeloproliferative neoplasms polycythemia vera, essential thrombocythemia, and primary myelofibrosis (PMF). These conditions are commonly linked to driver mutations in JAK2, CALR, and MPL. Rare cases with both BCR-ABL1 rearrangement and JAK2 V617F mutation have been reported. However, standardized and effective treatments are lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>Herein, we report a patient with PMF who progressed to accelerated CML. Initially, molecular genetic analyses revealed a JAK2 V617F mutation but no BCR-ABL1 rearrangement and the patient was diagnosed with PMF. Nine years after the initial PMF diagnosis, the patient was diagnosed with accelerated CML. Next-generation sequencing confirmed the presence of a BCR-ABL fusion and JAK2 V617 mutation. A combination of 20 mg ruxolitinib twice daily and 0.6\u00a0g flumatinib daily was prescribed as treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Serial quantitative measurements of the expression of BCR-ABL and JAK2 V617F following treatment with flumatinib demonstrated a marked reduction in the levels of the BCR-ABL transcripts, with a concomitant increase in the JAK2 V617F allele burden, suggesting that the two disorders arose from independent clones. The case presented suggests that the JAK2 V617F mutation and BCR-ABL fusion can coexist in early progenitor cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In the current case, the BCR-ABL fusion was detected and CML was confirmed after the recurrence of splenomegaly. Subsequent treatment with a combination of flumatinib and ruxolitinib was demonstrated to be safe and effective.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000003075","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T17:01:30Z","timestamp":1740675690000},"page":"1750-1754","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of JAK2 V617F-positive primary myelofibrosis and advanced chronic myelogenous leukemia with ruxolitinib and flumatinib: a case report"],"prefix":"10.1097","volume":"87","author":[{"given":"Feng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"R1-20250422","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":". Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R2-20250422","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"R3-20250422","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250422","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"R5-20250422","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12032-012-0398-2","article-title":"Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation","volume":"30","author":"Jurisic","year":"2013","journal-title":"Med Oncol"},{"key":"R6-20250422","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","article-title":"BCR-ABL1 is a secondary event after JAK2 V617F in patients with polycythemia vera who develop chronic myeloid leukemia","volume":"121","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"R7-20250422","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","article-title":"JAK2 V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders","volume":"22","author":"Cambier","year":"2008","journal-title":"Leukemia"},{"key":"R8-20250422","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/bcj.2015.77","article-title":"Concomitant JAK2 V617F-positive polycythemia vera and BCR\u2013ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib","volume":"5","author":"Zhou","year":"2015","journal-title":"Blood Cancer J"},{"key":"R9-20250422","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","article-title":"Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia"},{"key":"R10-20250422","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/blood-2011-07-365007","article-title":"Concomitant occurrence of BCR-ABL and JAK2V617F mutation","volume":"118","author":"Pieri","year":"2011","journal-title":"Blood"},{"key":"R11-20250422","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2012.47.8669","article-title":"Emergence of a BCR-ABL translocation in a patient with the JAK2 V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2 V617F clone","volume":"32","author":"Yamada","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-20250422","doi-asserted-by":"crossref","first-page":"710","DOI":"10.5858\/arpa.2021-0096-OA","article-title":"Sequential development of JAK2V617F mutation and BCR-ABL1 fusion in individual patients with myeloproliferative neoplasms","volume":"146","author":"Zhao","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"R13-20250422","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"R14-20250422","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/JS9.0000000000000373","article-title":"The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines","volume":"109","author":"Sohrabi","year":"2023","journal-title":"Int J Surg Lond Engl"},{"key":"R15-20250422","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1470-2045(07)70295-4","article-title":"Insights into JAK2 V617F mutation in CML","volume":"8","author":"Bocchia","year":"2007","journal-title":"Lancet Oncol"},{"key":"R16-20250422","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12185-009-0471-6","article-title":"A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders","volume":"91","author":"Bee","year":"2010","journal-title":"Int J Hematol"},{"key":"R17-20250422","first-page":"34","article-title":"The concomitant occurrence of JAK2V617F mutation and BCR\/ABL transcript with phenotypic expression-an overlapping myeloproliferative disorder or two distinct diseases?-case report","volume":"15","author":"Ursuleac","year":"2013","journal-title":"J Med Life"},{"key":"R18-20250422","doi-asserted-by":"crossref","first-page":"1391078","DOI":"10.3389\/fcell.2024.1391078","article-title":"Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease","volume":"12","author":"Zanelli","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"R19-20250422","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","article-title":"Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2V617F mutation: a multi-institutional study from the bone marrow pathology group","volume":"31","author":"Soderquist","year":"2018","journal-title":"Mod Path"},{"key":"R20-20250422","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00277-015-2518-5","article-title":"Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib","volume":"95","author":"Paz","year":"2016","journal-title":"Ann Hematol"},{"key":"R21-20250422","doi-asserted-by":"crossref","first-page":"e2021062","DOI":"10.4084\/MJHID.2021.062","article-title":"Is allogeneic transplantation an option in patients affected by concurrent myelofibrosis and chronic myeloid leukemia (CML)?","volume":"13","author":"Sora","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:01:48Z","timestamp":1745312508000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003075","relation":{},"ISSN":["2049-0801"],"issn-type":[{"type":"electronic","value":"2049-0801"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-08-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}